3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Terminated
1
Recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Observational
1
Sponsor
Cancer Type
Genitourinary
2
Conditions
Urinary Bladder Neoplasms
41
Non-Muscle Invasive Bladder Neoplasms
25
Colorectal Neoplasms
20
Anus Neoplasms
17
Carcinoma, Transitional Cell
15
Neoplasm Metastasis
12
Carcinoma, Hepatocellular
10
Appendiceal Neoplasms
10
Stomach Neoplasms
9
Peritoneal Neoplasms
9
Pancreatic Neoplasms
8
Carcinoma, Non-Small-Cell Lung
7
Neoplasms
6
Lung Neoplasms
6
Colonic Neoplasms
6
Rectal Neoplasms
5
Liver Neoplasms
5
Sarcoma
4
Anal Canal Carcinoma
4
Urologic Neoplasms
3
Urologic Diseases
3
Urinary Bladder Diseases
3
Pseudomyxoma Peritonei
3
Mesothelioma, Malignant
3
Gastrointestinal Neoplasms
3
Carcinoma in Situ
3
Carcinoma
3
Breast Neoplasms
3
Urogenital Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Interventions
pembrolizumab
5
padeliporfin
5
Nivolumab
5
fludarabine
4
aldesleukin
4
Ipilimumab
4
Cyclophosphamide
4
atezolizumab
3
Specimen Handling
3
Paclitaxel
3
Magnetic Resonance Spectroscopy
3
Gemcitabine
3
Carboplatin
3
vedolizumab
2
olaparib
2
niraparib
2
motexafin gadolinium
2
cabozantinib
2
anlotinib
2
abiraterone
2
Therapeutics
2
Sunitinib
2
Standard of Care
2
Riluzole
2
Radiation Dose Hypofractionation
2
Prednisone
2
Pluvicto
2
Mitomycin
2
LDP-02
2
Infliximab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Urogenital Neoplasms
×
Mitomycin
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled
NCT01200992
2017-08-24
EMBARC-RF
Bioniche Life Sciences Inc.
Phase 3
Terminated
84 enrolled
7 charts